Literature DB >> 10928065

Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.

L E Simonsen1, U Wählby, M Sandström, A Freijs, M O Karlsson.   

Abstract

AIM: To study the effects of single and fractionated doses of 5-fluorouracil and epirubicin on the leukocyte counts in rats.
METHODS: Six different dosing patterns of each drug were injected within one day. The leukocytes were followed for 11-15 days. Pharmacokinetic models were developed using NONMEM. Quantitative and qualitative pharmacokinetic-pharmacodynamic relationships were investigated.
RESULTS: A one-compartment model with non-linear elimination described 5-fluorouracil pharmacokinetics and a three-compartment model described epirubicin concentration data. Sigmoidal or basic Emax-models quantified the relationships between individual AUCs and decreases in leukocytes, for both drugs. Similar relationships between AUC and toxicity were found, regardless of whether the drugs were given as single or fractionated doses.
CONCLUSION: Quantitative relationships between AUC and the effect on leukocytes were established for 5-fluorouracil and epirubicin. However, no schedule dependence was indicated for the schedules used in the study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928065

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

Review 2.  Array of translational systems pharmacodynamic models of anti-cancer drugs.

Authors:  Sihem Ait-Oudhia; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-10-22       Impact factor: 2.745

3.  Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model.

Authors:  Lena E Friberg; Marie Sandström; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2009-08-27       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.